abstract: The objective of these studies was to identify differentially expressed peptides/proteins in the culture media of embryos grown during in vitro fertilization (IVF) treatment to establish their value as biomarkers predictive of implantation potential and live birth. Micro-droplets of embryo culture media from IVF patients (conditioned) and control media maintained under identical culture conditions were collected and frozen at 2808C on Days 2 -3 of in vitro development prior to analysis. The embryos were transferred on Day 3. The peptides were affinity purified based on their physico-chemical properties and profiled by mass spectrometry for differential expression. The identified proteins were further characterized by western blot and ELISA, and absolute quantification was achieved by multiple reaction monitoring (MRM). We identified up to 14 differentially regulated peptides after capture using paramagnetic beads with different affinities. These differentially expressed peptides were used to generate genetic algorithms (GAs) with a recognition capability of 71 -84% for embryo transfer cycles resulting in pregnancy and 75-89% for those with failed implantation. Several peptides were further identified as fragments of Apolipoprotein A-1, which showed consistent and significantly reduced expression in the embryo media samples from embryo transfer cycles resulting in viable pregnancies. Western blot and ELISA, as well as quantitative MRM results, were confirmatory. These results demonstrated that peptide/protein profiles from the culture medium during early human in vitro development can discriminate embryos with highest and lowest implantation competence following uterine transfer. Further prospective studies are needed to establish validated thresholds for clinical application.
Introduction
Assisted reproductive technologies (ART) provide infertile couples with a unique means of achieving a pregnancy. Global statistics unequivocally demonstrate increasing pregnancy rates worldwide since the inception of the techniques in the early eighties (Society of Assisted Reproductive Technologies, SART, 2009; Centers for Disease Control and Prevention, CDC, 2010; de Mouzon et al., 2010) . As a result, more and more couples with a variety of diagnoses of female and/or male infertility are successfully being treated by in vitro fertilization (IVF) and uterine transfer of fresh and/or cryopreserved-thawed embryos. Today, over 1% of all infants born in the USA and up to 4% in some European countries every year are conceived using ART (Nygren and Andersen, 2002; Schieve et al., 2009) . The discovery of a non-invasive method of identifying biomarkers of embryo developmental capacity during the in vitro culture period could significantly contribute to the optimization of ART by allowing (i) an improved selection of embryos with highest implantation competence for uterine transfer and (ii) a concomitant reduction in the number of embryos transferred per attempt, leading to a decrease of the medical complications and economic burden to the health system determined by the occurrence of multiple gestations.
For ethical reasons, studies focusing on early human embryo development in vitro have been largely descriptive. Normal, IVF-derived human embryos donated for research are not readily available; as a consequence, only limited research has been performed with 'discarded' embryos that not necessarily provide physiologic information. The ability to screen the embryos in the IVF laboratory using inverted light microscopy to ascertain which embryo has the highest chance of implantation has received full attention, but the examination of zygote/embryo morphology, cleavage status and blastomere development up to the blastocyst stage are only predictive to a limited extent. On the other hand, the invasive method of preimplantation genetic screening using fluorescence in situ hybridization following an embryo biopsy has been used with great controversy in order to establish embryo euploidy, and it remains to be established whether newer technologies such as comparative genomic hybridization and microarrays can be more efficient and clinically applicable (Harper and Harton, 2010; Meseguer et al., 2012; Treff and Scott, 2012) .
The scientific focus in ART has therefore partially shifted to the evaluation of non-invasive methods of assessing embryo developmental capacity/normalcy under in vitro culture conditions. Non-invasive methods examined so far have been based on the measurement of metabolic determinants of embryo viability (i.e. determinations of pyruvate, glucose, amino acid, oxygen modifications) (Sturmey et al., 2008) . More recently, the analysis of the proteome/secretome and metabolome of the developing embryo during days of in vitro culture has been introduced (Katz-Jaffe et al., 2009; Seli et al., 2010; Nel-Themaat and Nagy, 2011 ). An ideal biomarker should be specific, easily detectable with minimum or no invasion and should be present at the earliest stages of the process under consideration. In the ART scenario, the biomarker(s) should have a positive impact on clinical management with robust statistical power for prediction of implantation and normal post-implantation embryonic development. However, so far, there is no unequivocal demonstration of a biomarker(s) with high predictive power in the clinical arena.
During the 2-5 days of exposure to the IVF micro-environment, embryos undergo an orderly and sequential adjustment to culture conditions that are reflected in dynamic changes in their metabolism and secretory patterns. It is our hypothesis that early secretory proteins analyzed from the culture medium, and/or changes in the composition of the culture medium exposed to embryos, can be detected and quantified by biochemical methods with high sensitivity and specificity providing information about embryo growth, developmental and implantation competences. As such, the more viable embryos might exhibit defined changes in their culture milieu including, (i) a unique protein/peptide fingerprinting, such as presence of defined secretory proteins not previously present in the medium and/or (ii) modification of the culture medium resulting in reproducible profiles associated with depletion or augmentation of specific proteins/peptides. These profiles should then be tested in prospective, blinded studies, in order to statistically distinguish viable versus non-viable embryos with high accuracy and reproducibility.
The aim of this study was to use a proteomics approach to identify biomarkers in the embryo culture medium during IVF treatment and to establish their prognostic value as predictors of embryo developmental competence, including implantation and full-term pregnancy potential, following uterine transfer.
Materials and Methods

Patient population
This prospectively designed clinical investigation was approved by the Institutional Review Board of Eastern Virginia Medical School. All consenting IVF patients and donor egg recipients were included in the study irrespective of the woman's age (range 26 -48 years), infertility diagnosis (female or male), ovarian stimulation protocol (use of GnRH agonist or antagonist protocols in combination with recombinant and/or highly purified urinary gonadotrophins), or performance of conventional IVF or ICSI. Only 'fresh' embryo transfer cycles were considered (no cryopreservedthawed embryo transfer cycles were studied). The period of the study was from January 2006 through December 2010. Patient demographics, infertility diagnosis and evaluation, ovarian stimulation protocols, laboratory procedures and embryo transfer techniques used in our center during the last decade have been summarized elsewhere (Mirkin et al., 2003; Arslan et al., 2005; Oehninger, 2011) . In all cases, embryo transfer was performed on Day 3 of in vitro culture (cleavage stage). In the last few years, the policy of our program has been to recommend the transfer of two embryos, with only occasional transfer of three embryos in patients of advanced maternal age and multiple previous failures (Dowling-Lacey et al., 2007; Riggs et al., 2010) . Single-embryo transfer was performed if the patient requested it (elective), or if only one embryo was available for transfer.
Following the prospective collection of embryo culture fluids from consenting patients, IVF outcomes were retrospectively analyzed. All IVF data are routinely stored in a computerized database following the guidelines established by SART. A pregnancy (live birth) was defined as initially appropriately rising b-hCG serum titers, followed by ultrasound demonstration of a viable embryo by positive fetal heart beat at 7 weeks' gestation and delivery after 37 weeks' gestation.
Embryo culture medium sample preparation
Immediately after fertilization assessment (pronuclear stage, Day ¼ 1), embryos were cultured individually in microdroplets under oil at 378C in a humidified incubator at 5% CO 2 in a total volume of 50 ml. Embryos were cultured in P1 medium (Irvine Scientific, Santa Ana, CA, USA) supplemented with 10% serum synthetic substitute (SSS, Irvine). All embryos derived from the cohort of retrieved follicles/oocytes were included in the study. Embryos of poor quality (morphology scores .3), having abnormal cleavage or demonstrating developmental arrest were deselected as per policy (Veeck, 1984; Dowling-Lacey et al., 2007) . The culture medium was changed daily and samples from Days 2 (typically two to four cell stage embryos) and 3 (typically six to eight cell stage embryos) were collected (embryo 'conditioned media'). On Day 2 after embryo transfer to the new culture droplet, and on Day 3 prior to uterine embryo transfer, cryopreservation or deselection, the complete amount of conditioned media from each embryo was collected, divided into two aliquots of 20 ml each, and immediately frozen at 2808C. In a parallel control experiment for each patient, blank culture media (P1 + SSS) (without an embryo) were treated in an identical manner for 2 or 3 days in culture and frozen (embryo 'control'-blank media).
Experimental design
Experiments were designed to fulfill the following specific aims: (1) To determine the full protein composition of the SSS-supplemented P1 control culture medium using an LC-ESI-MS/MS approach [liquid chromatography electrospray ionization tandem mass spectrometry (MS)]. (2) To compare embryo culture media (conditioned and control) profiles obtained with four different affinity-purification strategies using ClinProt TM (Bruker Daltonics, GmbH, Bremen, Germany) paramagnetic beads with different surface chemistries. The beads with the following functional properties were used to capture peptides from conditioned and control IVF media prior profiling by MS: (i) C-8 beads (hydrophobic interaction), (ii) IMAC beads (immobilized metal affinity chromatography), (iii) weak cationic exchange (WCX) beads and (iv) weak anionic exchange (WAX) beads.
(3) To profile and compare peptide/protein expression between the different groups of culture media (based on known clinical outcome). For this purpose, the following groups were analyzed: (i) blank or control (C) media; (ii) not pregnant (NP) media (samples from transfers where no embryos implanted, i.e. no pregnancy followed the transfer of one, or two); (iii) mixed pregnant (MP) media (samples from transfers resulting in the establishment of a pregnancy but not all transferred embryos implanted, i.e. a singleton pregnancy after transfer of two or three embryos, or a twin pregnancy after transfer of three embryos; (iv) very pregnant (VP) media (samples where all transferred embryos established a pregnancy, i.e. a singleton pregnancy after a single embryo transfer, or a twin pregnancy after transfer of two embryos) and (v) deselected (D) media (samples from poor-quality embryos that were not transferred or cryopreserved). And (4) to establish a proteomic classification algorithm that can accurately determine the implantation capacity of individual embryos through identification of biomarkers with greatest discriminatory power.
Altogether, 1750 culture media samples (from culture Day 2 and Day 3) from 1000 individual embryos were studied.
Materials
All the reagents and chemicals used in the study were of the highest possible purity and quality available. Ammonium bicarbonate, iodoacetamide, dithiothreitol (DTT), trifluoroacetic acid and formic acid were obtained from Sigma-Aldrich (St Louis, MO, USA). High-performance liquid chromatography (HPLC)-grade acetonitrile and water were obtained from Fisher Scientific (Fairlawn, NJ, USA). MS-grade modified trypsin was from Promega (Madison, WI, USA). WCX kits, WAX kits, a-cyano-4-hydroxycinnamic acid (HCCA) and peptide and protein calibration standards were obtained from Bruker Daltonics (Billerica, MA, USA).
Identification of proteins in SSS-supplemented P1 culture medium by MS
In initial experiments, the full protein composition of the complete P1 medium with SSS was determined using an LC-ESI-MS/MS approach as follows. The protein concentration of the complete culture media was determined using the bicinchoninic acid (BCA) protein assay (Thermo Scientific Pierce, Rockford, IL, USA). Two hundred micrograms of the protein sample was dissolved in 50 mM ammonium bicarbonate before reduction using 10 mM DTT for 30 min at 568C, followed by alkylation with 55 mM iodoacetamide for 45 min at room temperature in the absence of light. The reduced and carbamidomethylated proteins were subjected to in-solution trypsin digestion using sequencing grade modified trypsin (Promega) at a molar ratio of 1:20 at 378C overnight (VerBerkmoes et al., 2002) . The resulting peptide mixture was purified using a ResPrep C18 column (Bellefonte, PA, USA). The eluted peptides were dried by speed-vac and reconstituted in buffer A (5% acetonitrile, 0.1% formic acid, 0.005% heptafluorobutyric acid) before LC-MS/MS analysis using a Thermo-Finnigan linear trap quadrupole (LTQ) mass spectrometer coupled to an Agilent 1100 nano-HPLC. The peptide mixture was fractionated using a 12 cm × 0.075 mm fused silica capillary column packed with 5 mM diameter C-18 beads (Michrom Bioresources, Auburn, CA, USA). The peptides were eluted by applying a 0-80% linear gradient of Buffer B (95% acetonitrile, 0.1% formic acid and 0.005% HFBA) over 300 min with a flow rate of 200 nl/min directly into the ion source.
Automated MS data acquisition was done using an instrument method composed of a single segment and five data-dependent scan events with a full MS scan followed by five MS/MS scans of the highest-intensity ions under the following conditions: a normalized collision energy of 35, an activation quadrupole of 0.250 and a minimum full scan signal intensity of 1 × 10 5 , without specifying the minimum MS/MS intensity. Dynamic exclusion was turned on, with a 3-min repeat count of 2 and the mass width was set at 1.0 m/z. After the MS/MS data processing, a database sequence search to identify the proteins was performed using an in-house MASCOT Daemon server (Matrix Science, London, UK) with the current non-redundant SwissProt protein database. The following parameters were used in the search: one missed cleavage site, fixed modification, carbamidomethylated cysteines; oxidation of methionine, deamidation of asparagines and glutamine as variable modifications; with a mass accuracy of 1.0 Da for MS and 0.5 Da for MS/MS data. This experimental strategy was used in similar experiments to identify proteins in IVF spent media from embryos with different clinical outcomes.
Embryo culture sample preparation for protein and peptide profiling
In follow-up experiments, four different affinity-purification strategies using ClinProt TM (Bruker Daltonics, GmbH) paramagnetic beads with different surface chemistries were evaluated for the profiling experiments. These experiments were used to determine the reagent to use in the subsequent profiling experiments based on the complexity of the spectra and differential expression profiles. The beads with the following functional properties were used to capture peptides from conditioned and control IVF media prior profiling by MS: (i) C-8 beads (hydrophobic interaction), (ii) IMAC beads (immobilized metal affinity chromatography), (iii) WCX beads and (iv) WAX beads. The WCX and WAX beads provided the most robust spectra with the greatest number of peptide peaks after MS. In subsequent analyses, peptides were affinity purified from spent IVF media samples using the WCX and WAX magnetic beads. The affinity-purification experiments were conducted according to the manufacturer's instructions with minor modifications with respect to sample, binding-solution and elution-solution volumes as described below.
Sample processing was done automatically using the ClinProt TM robot (Bruker Daltonics, GmbH), to reduce operator-induced variability. For each IVF spent medium sample (conditioned or control, 20 ml aliquot), duplicate experiments were performed by adding 20 ml of activating solution and mixed with either 10 ml of WAX or WCX magnetic beads in individual wells of a 96-well microtiter plate before discarding the supernatant. The magnetic beads were then equilibrated by washing twice using a binding buffer. Forty microliters of the same solution was added to the beads before adding 10 ml aliquots of randomized individual embryo media samples from each sample set (VP, MP, NP, C and D culture media samples). The supernatant was removed after a 5-min incubation period, and the beads were washed twice with 45 ml and once with 15 ml of the respective kit washing buffer. Peptides were then eluted with 10 ml of 50% acetonitrile and stored in a fresh 96-well microtiter plate under optimal conditions prior to MS.
MS profiling of affinity-purified peptides
Aliquots of all the eluted peptide samples (5 ml) were mixed with 20 ml of HCCA matrix solution containing 2 mg/ml HCCA in 1:3 ethanol/ isopropanol (v/v). One microliter of the matrix/peptide mixture from each sample was spotted onto a MALDI-time-of-flight (TOF) MTP 384 Anchor-Chip TM target (Bruker Daltonics) (Krause et al., 1991; Burnum et al., 2008) . As in the preceding section, all the preparation steps were done automatically using the ClinProt TM sample preparation robot. Mass spectra were acquired using an Ultraflex MALDI-TOF/TOF mass spectrometer (Bruker Daltonics) in the positive linear model to record m/z values from 1000 to 10 000 Da and in the positive reflectron mode to record m/z values between 1000 and 5000 Da. Prior to sample analysis, an external calibration was performed on the instrument using either the peptide (peptide mix1) or protein (protein mix1) calibration standards (Bruker Daltonics). In order to obtain high-quality spectrum profiles and fast measurements, automated MS analysis was performed using the AutoXecute module of the FlexControl TM 3.0 acquisition software (Bruker Daltonics) under the following settings: Linear positive mode; ion source 1, 25.19 kV; ion source 2, 23.59 kV; lens 6.53 kV; pulsed ion extraction 100 ns; detection range 700 -20 000 Da. We used a high gating factor with signal suppression up to a M r of 700 for suppression of matrix and matrix adducts signals. For the reflectron positive mode, the following conditions were used: ion source 1, 25.13 kV; ion source 2, 21.68 kV; lens 9.34 kV; pulsed ion extraction 100 ns; reflector 1, 26.40 kV; reflector 2, 13.76 kV; the detection range 700 -5000 Da. The gating and matrix suppression conditions were as in the linear mode. For each sample, each of the four replicates in the four spots was measured. For each spot, 3000 spectra were acquired (500 shots at 6 different random spots). All signals with a signal-to-noise (S/N) ratio of .3 in the mass ranges defined above were processed using the FlexAnalysis TM 3.0 software (Bruker Daltonics) before further analyses.
Data processing and statistical analysis
Data analysis was performed using the ClinProTools TM 2.1 software (Bruker Daltonics). Multiple spectra from the different IVF spent media categories were compared for pattern identification and recognition as follows: in an initial step, each raw spectrum was normalized to its total ion current before recalibration using the prominent common m/z values. The spectra were then processed by baseline subtraction, smoothed using optimal parameters and the peaks were detected using a S/N ratio of 3 before calculating the peak areas for each spectrum. Peak areas were calculated using end-point level integration type. Spectra were also 'top hat' baseline subtracted with the minimum baseline width set to 10%, smoothed and processed in the 1 -10 kDa range. Basic statistical analysis, GA and support vector machine (Dennis et al., 2003) were then used for the selection of signal/peak clusters that were able to differentiate between the different IVF spent media categories. These signals/peaks were preliminarily tested for their predictive capability using the four different data sets separately. The receiver operating characteristic curve analysis and area under the curve (AUC) calculation were performed by the ClinProTools TM 2.1 software to determine the predictive value of each single marker. The cut-off value (P , 0.0001) corresponding to the highest accuracy (the lowest false-negative and false-positive results) was also calculated, together with specificity and sensitivity (Vapnik, 1998) .
Base-line subtraction, normalization (to total ion current), peak detection and spectral alignment were performed using a mass window of 0.3% and a S/N ratio of 3 for peak detection. A GA using k-nearest neighbors was used to obtain a classification between embryo media classes. The result of the GA is the peak combination which is proved to separate best between the different classes. Significant differences between groups were determined by Student's t test.
Tandem MS analysis to identify differentially expressed peptides
The tandem mass spectra for the differentially expressed peptides were acquired on the Ultraflex MALDI-TOF/TOF mass spectrometer using the LIFT module under the following conditions: reflectron mode accelerating voltage of 6.01 kV, an extraction voltage of 5.26 kV, a lens voltage of 2.96 kV, a reflector voltage of 27.04 kV, a lift 1 voltage of 19.17 kV and a lift 2 voltage of 3.86 kV (Suckau et al., 2003) . The LIFT TOF-TOF spectra were the sum of 500 -2200 laser shots and were automatically processed in FlexControl TM 3.0 (Bruker Daltonics). Processing included one cycle of a Savitzky-Golay smoothing algorithm with a width of 0.2 and baseline subtraction using a TopHat algorithm. The processed MS/MS data were used in database sequence searches to identify the peptides using an in-house MASCOT Daemon server (Matrix Science) with the current nonredundant SwissProt protein database. The following parameters were used in the search: no enzyme used, variable oxidation of methionine residues and a mass accuracy of 1.0 Da for MS and 0.5 Da for MS/MS data.
Western blot analyses of conditioned and control IVF culture media samples
To confirm the presence of specific proteins in the spent IVF culture media, normalized concentrations of 5 -10 sets of pooled embryo media samples (from each category of VP, MP, NP, D and C) were analyzed by western blot. Two hundred micrograms total protein equivalent of each sample was subjected to 4 -12% gradient SDS-polyacrylamide gel electrophoresis gel electrophoresis (Invitrogen, Carlsbad, CA, USA) and then transferred to nitrocellulose membrane (Millipore, Bedford, MA, USA). The membranes were incubated with blocking solution (0.1% Tween 20-Tris-buffered saline buffer containing 10% non-fat dry milk) for 1 h and incubated with the corresponding antibodies at 48C overnight (polyclonal anti-human Apolipoprotein A-1 diluted 1:5000) (Abcam, Cambridge, MA, USA). The membranes were washed before incubation for 1 h with donkey anti-goat immunoglobulin (IgG) fluorescent labeled secondary antibody CW 800 diluted 1:100 000 (Abcam). The immunoblots were visualized using the Odyssey Imaging system (Li-Cor Biosciences, Lincoln, NE, USA) according to the manufacturer's instructions. The quantification of the western blots was done using laser densitometry.
ELISA of conditioned and control IVF culture media samples
Quantification of Apolipoprotein A-1 in five pooled embryo media samples (from each category of VP, MP, NP, D and C) was done using a recombinant Apolipoprotein A-1 standard (Abcam). The ELISA experiment was conducted using a modified experimental protocol as follows: Briefly, serial dilutions of the Apolipoprotein A-1 protein standard were done using phosphate-buffered saline (PBS) to obtain a concentration range from 40 to 1.25 ng in a final volume of 50 ml. The diluted samples were used to coat adjacent duplicate wells in ELISA plates. The total protein concentration in each of the five sample categories (VP, MP, NP, D and C) was determined by BCA assay. For each of the five sample categories, seven serial dilutions were done from 40 ng down to 1.25 ng in 50 ml of coating buffer. The diluted samples were used to coat the microtiter ELISA plates after overnight incubation at 48C. The samples were decanted from the wells and the plates washed four times using 100 mM phosphate buffered saline, pH 7.2, containing 0.05% Tween 20. To minimize non-specific binding by the second antibody, 200 ml of blocking solution 0.5% BSA in PBS/T20 was added to each well before incubation for 2 h at 378C. The wells were rinsed with PBS to wash unbound blocking reagent before transferring 100 ml of the primary antibody (polyclonal goat anti-Apolipoprotein A-1) diluted 1:1000 in the blocking solution to the wells and incubating at 378C for 2 h. The primary antibody was removed from wells and the plates washed four times using PBS/T20 before the addition of 100 ml of secondary antibody [donkey anti-goat IgG peroxidise conjugate (Santa Cruz Biotechnology, CA, USA)], diluted 1:4000 in blocking solution. After 1 h incubation at 378C, the secondary antibody was removed from the wells and plates washed four times using PBS/T20. The amount of Apolipoprotein A-1 present was assayed by measuring peroxidase activity of the secondary antibody as follows: 100 ml of tetramethylbenzidine was added to each well and incubated at room temperature for 10 min in the absence of light. The development of color was stopped by adding 100 ml of 1N sulfuric acid. The optical density was read at 45 nm on a PowerWaveX Microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA). Each of the duplicate media samples was assayed 3 times to provide 12 estimates of each condition and all the 12 estimates were analyzed simultaneously to allow a comparison of relative amounts of antigen compared with the standard curve generated using the recombinant Apolipoprotein standard. Further ELISA experiments were carried out with individual media samples from all categories of clinical outcomes (VP, MP, NP, D and C).
Quantitative multiple reaction monitoring analyses
An absolute quantification (AQUA) stable isotope peptide for an Apolipoprotein A-1 peptide (DEPPQSPWDR) that was found to be differentially expressed in the experiments described in the preceding methods section was synthesized. The C-terminal arginine residue contained the stable heavy isotopes for the elements carbon and nitrogen thus giving the peptide a +10 Da increase in molecular mass. The AQUA peptide was used to develop an internal standard calibration curve in a multiple reaction monitoring (MRM) experiment to determine the limits of detection and quantification (LOQ and LOD, respectively). The following MRM transition pairs were used: Endogenous Apolipoprotein A-1 peptide DEPPQSPWDR Q 1/Q3 and for the AQUA peptide DEPPQSPWDR* (*C-13, 6; N-15, 4) Q1/Q3 the collision energies were optimized using the MRM Pilot TM software for the targeted proteins and peptides. For the analysis of the embryo media samples, the IVF fluids were diluted 1:10 using 0.1% formic acids. The AQUA peptide was spiked at a final injection concentration of 250 femtomole before analysis. Nano-LC-MRM/MS analyses was performed in a hybrid triple quadrupole/linear ion trap mass spectrometer 4000 (QTRAP w LC/MS/MS system, AbiSciex, Foster City, CA, USA) coupled to a Tempo NanoLC system (Eksigent Technologies, Dublin, CA, USA) under the following conditions: solvent A, 0.1% formic acid; solvent B, 95% acetonitrile in 0.1% formic acid; flow rate, 500 nl/min; gradient, 5 -10% solvent B in 3 min, 10 -60% solvent B in 48 min and 60 -95% solvent B for 5 min before re-equilibration for with 95% B for 7 min; column, PicoFrit columns (75 mm inner diameter, 10 mm tip opening (New Objective, Woburn, MA, USA) with slurry-packed in house with 10 cm of reverse-phase 5 mm 100 Angstrom Magic C18 resin (Michrom Bioresources). Data acquisition was performed with an ion spray voltage of 2800 V, curtain gas of 20 p.s.i., nebulizer gas of 10 p.s.i. and an interface heater temperature of 1258C. Collision energy, declustering potential and collision cell exit potential were optimized for maximum transmission and sensitivity of the MRM transitions. A minimum dwell time of 10 ms was used in all the experiments. Two MRM transitions per peptide were monitored and acquired at unit resolution both in the first and third quadrupoles (Q1 and Q3) to maximize specificity. All LC-MRM/MS experiments were performed in three triplicates. Data analysis was performed using the MultiQuant software TM (ABI Sciex, Foster City, CA, USA). The relative ratios of the most abundant transition for each pair were used for quantification.
Results
Identification of proteins in SSS-supplemented culture medium by MS
The first goal of the study was to characterize the complete P1-medium-SSS proteome in order to produce a highly confident protein composition list. MS output data from triplicate digests from each LC-MS/MS ran were searched separately using Mascot daemon (Matrix Science). All the three protein lists were integrated to produce a master list of proteins that appeared in at least two of the three lists. This resulted in 50 proteins with a .95% confidence limit using at least two peptides to identify each protein. The list of the P1-SSS medium proteins including detailed information on their putative physical and functional properties is presented as reference for future proteomics studies (Supplementary data, Table SI ). In order to evaluate the quality of the P1-SSS media proteome, a comparison was made using the published catalog of human plasma and human serum proteins deposited in the Peptide Atlas database of the Institute for Systems Biology at the Seattle Proteome Center https://db.systemsbiology.net/sbeams/cgi/PeptideAtlas/Search. All the proteins that were identified in the P1-SSS media have been previously identified in plasma and serum proteomics projects under the auspices of the Human Proteome Organisation, confirming that the SSS medium is a human serum derivative as stated by the manufacturer's catalog.
MS profiling of WXC affinity-purified peptides and GAs
Initial pilot studies demonstrated that the intensity of the peptides was highest in the WCX profiles compared with the other three surfaces, WAX, IMAC and C8 (data not shown). Therefore, WCX surfaces were chosen for the next experiments where mass spectra were acquired using the Ultraflex MALDI-TOF/TOF mass spectrometer in the positive linear mode. In the first study, the profiles of conditioned IVF culture media from Day 2 and Day 3 embryos of the groups of MP, NP and blank controls (C), were compared to determine whether there were differences in expression profiles at 48 or 72 h post fertilization. Since fluids from the VP group were fewer, these media were not analyzed until the reliability of the method could be ascertained. GAs were constructed to classify the embryo transfer cycles which resulted in a successful pregnancy versus those that did not. A total of 702 samples (1404 spectra, duplicates) were analyzed, including 356 day 2 samples (177 NP, 73 MP and 106 blank C) and 346 day 3 samples (159 NP, 84 MP and 103 blank C).
The classification algorithm for Day 3 transfers demonstrated a recognition capability (after cross validation) of 41% for pregnancy (MP) and 72% for failure to establish a pregnancy (NP). Similar results were obtained for Day 2 transfers (recognition capability of 40% for MP and 83% for NP). These GAs were based on the identification of 11 peaks (data not shown). For Day 3 embryos, among these 11 peaks, peptides with peaks at m/z 2454, 2648, 2684, 2705 and 2778 showed significantly reduced expression in the culture media samples from embryos that produced a pregnancy (MP) compared with NP ones (P , 0.05). Figure 1A shows the cluster analysis from sample sets of Day 3 embryos for NP, MP and C groups following WCX profiling (using peaks at 2420 and 2149 m/z). Results show a clear trend for separation of control groups and of MP and NP samples. For Day 2 embryos, among the 11 peaks, peptides with peaks at m/z 2110, 2381, 2648, 3354 and 4096 showed significantly reduced expression in the culture media samples from embryos that produced a pregnancy (MP) compared with NP ones (P , 0.05). Most of these peaks were identified to be Apolipoprotein A-1 fragments after tandem MS/MS and database searches using Mascot (www.matrixscience.com). Other peaks could not be identified because of low expression.
Since the information derived from the study of the MP group is confounded by the fact that not all the transferred embryos implanted, we performed a follow-up experiment using a set of 'unique' samples of the VP group, where all transferred embryos resulted in a live birth. A total of 20 samples (40 spectra, duplicates) from each Day 2 and Day 3 transfers from the VP group were tested as unknowns using the algorithms mentioned above. Results indicated that the Day 2 and Day 3 samples were classified correctly (successful implantation) in 57 and 67% of the cases, respectively, thereby improving the initial results obtained from the MP samples.
Further profiling experiments were performed using embryo media from deselected embryos (D) in addition to the MP, VP, NP and C groups. We aimed to examine whether the same peaks found to be discriminatory in the study using media samples from transferred embryos were also able to discriminate deselected embryos (i.e. the discarded embryos of poorest quality). Twenty samples were used from each of the media sample categories and a new algorithm was developed to classify deselected versus transferred embryos (VP, MP and NP) using seven peaks (not shown). A cluster analysis of Day 3 embryos with ClinProTools using WAX beads is shown in Fig. 1B (using peaks at m/z of 1241 and 1243), which clearly distinguished the group of deselected embryos from the other groups.
MS profiling of tandem WAX and WXC affinity-purified peptides
Next, we performed sequential affinity purification using WAX and WCX paramagnetic beads prior to profiling by MS. Using this approach, randomized samples consisting of 30 individual conditioned IVF media from MP, 30 individual conditioned IVF media from NP and 30 individual spent blank IVF media samples (C) were affinity purified using the WAX beads in the first step to capture negatively charged peptides. The unbound fraction was subjected to a second affinity-purification step using the WCX beads to capture the positively charged peptides. All the purification, elution and sample spotting steps were automatically done using the ClinProt robot. Each of the individual bound fractions was eluted and spotted four times on an AnchorChip MALDI target (n ¼ 360) for each sample group prior to automatic analysis using the Ultraflex mass spectrometer with the reflectron mode as described in the Materials and Methods section. The resulting spectra were separated based on class (MP, NP and C) and the ClinProTools TM bioinformatics software (version 2.0 build 365) was used to generate a composite spectrum for each sample set using individual spectra generated from each sample after the WAX and WCX affinity capture and MS.
The composite spectra were analyzed to identify peaks with statistically different expression profiles between the sample sets. In the WAX profiling, out of the 63 identified peaks, 14 peaks with m/z 1041. 69, 1096.62, 1226.57, 1299.76, 1680.86, 1779.92, 1902.87, 1917.05, 1997.96, 2430.43, 3193.64, 3251.66, 3340.76 and 222.65 were found to be differentially expressed (P , 0.05). The peptides with m/z 1041. 69, 1096.62, 1226.57, 1299.76 and 4222.65 were present at higher intensities in the NP and the blank (C) sample sets compared with the MP samples (P , 0.05). These results suggest that the 'good quality' embryos that resulted in pregnancies after transfer actively take up (internalize/metabolize) these peptides (or proteins), whereas the 'poor quality' embryos that failed to establish pregnancies do not. In contrast, the peptides with m/z 1680. 86, 1779.92, 1902.87, 1917.05, 1997.96, 2430.43, 3193.64, 3251.66 and 3340.76 were present at higher intensities in the pregnant sample set compared with the NP and the blank sample, suggesting that these peptides (proteins) are not taken up by the successful embryos. In these analyses, no peptides were found to be exclusively present in one sample set.
On the other hand, in the WCX profiling out of the 37 peaks detected in the analysis, 11 peaks with m/z 1200. 78, 1331.83, 1453.91, 1468.83, 1603.93, 1692.20, 1708.00, 1816.94, 2109.56, 2165.27 and 2199.24 were found to be differentially expressed (P , 0.05). A typical raw MS/MS LIFT spectrum with WCX purification is shown in Supplementary data, Fig. S1 . All these peptides were present at higher intensities in the NP and the blank sample (C) sets compared with the MP. These results provide further evidence to suggest that the 'good quality' embryos that resulted in pregnancies after transfer are actively taking up these peptides (or proteins), whereas the 'poor quality' embryos that failed to establish pregnancies do not.
These differentially expressed peptides were used to establish a new GA to classify or statistically distinguish embryo transfers that resulted in pregnancy versus those that did not. For the WAXprocessed samples, the GA had a recognition capability (after cross validation) of 71% for the MP group. Therefore, this profile could correctly predict successful implantation 71% of the times. For the NP group, the GA had a recognition capability of 88%, so that the selection of these embryos would have predicted an 88% likelihood of failed implantation (thereby providing good information for selecting embryos at the time of transfer). For the WCX-processed samples, the GA had a recognition capability of 84% for the MP samples after cross-validation. For the NP samples, the GA had a recognition capability of 75%. Therefore, these new algorithms substantially improved the prediction of embryo implantation capacity.
Identification of differentially expressed peptides/proteins
Further identification of the differentially expressed peptides in these samples was carried out using the LIFT function of the Ultraflex III TOF-TOF mass spectrometer. This approach resulted in the identification of the highly abundant peptide with m/z 1226.57 directly from the samples that were used in the WAX profiling experiments. The corresponding MS/MS spectra are shown in Fig. 2A (for the parent ions), Fig. 2B (for the fragment ions) and Fig. 2C (from in silico fragmentation). The database sequence analysis (MASCOT annotation) identified the peptide to be derived from the protein Apolipoprotein A-1 (ion score ¼ 75, P , 0.0001). The peak intensities of the Apolipoprotein A-1 peptide 1226.57 and the distributions in samples from the MP, NP and C groups are shown in Fig. 3A . A significantly different expression was observed comparing MP and NP samples (P , 0.05) as presented in Fig. 3B .
To further improve on the identification rates, another complementary approach was used to identify the differentially expressed peptides described in the preceding section. Here, the WAX and WCX affinity-purification procedure was repeated in 10 replicates using pooled media samples from the pregnant (MP) and the groups. The eluted peptides were combined and concentrated before analysis by LC-ESI-MS-MS on a Thermo Finnigan LTQ mass spectrometer. In this approach, peptides are first separated on a reverse-phase C18 column before MS analysis in the linear trap quadrupole instrument. We identified three other Apolipoprotein A-1 peptides with m/z 1200.78, 1468.83 and 1816.94 that were differentially expressed after WCX profiling and that showed a significant reduction in the pregnant samples (P , 0.05).
Western blot analysis of Apolipoprotein A-1
To confirm the observation that Apolipoprotein A-1 is selectively taken up by viable embryos, normalized amounts of five sets of media (VP, MP, NP, D and C groups) were analyzed by western blotting. Pooled samples of 5-10 samples per group were tested and the results were consistent with the MS profiling data showing that there are lower amounts of Apolipoprotein A-1 in pregnant samples compared with non-pregnant and with deselected embryos and blank controls (C . D . NP . MP . VP). Figure 4A , upper panel, shows results of intensity of fluorescence as determined by laser densitometry. The average intensity from each band is consistent with the MS profiling data showing that there are lower amounts of Apolipoprotein A-1 in VP samples compared with NP, deselected (D) and blank (C) media samples. Figure 4B , lower panel, shows a representative blot with the albumin control.
ELISA for Apolipoprotein A-1 ELISA was performed in duplicate media samples and assayed 3 times to provide 12 estimates of each condition and all the 12 estimates were analyzed simultaneously to allow a comparison of relative amounts of antigen compared with the standard curve generated using the recombinant Apolipoprotein standard. The ELISA results of pooled samples from the five groups (n ¼ 5 samples per category) confirmed lower amounts of Apolipoprotein A-1 in pregnant samples compared with non-pregnant and with deselected embryo samples as well as blank controls. The amount of Apolipoprotein A1 in the IVF culture media decreased in the following order: C . D . NP . VP . MP using 100 ng total protein input (Fig. 4B, upper panel) . The highest reduction in the amount of Apolipoprotein A-1 was observed in the MP and the VP groups where the amount of the protein was 33 and 17%, respectively, lower compared with the control media. The percentage reduction in the other media categories compared with controls was 4 and 7%, for the deselected media (D) and NP media, respectively. Again, the general observed trend was the reduction of the amount of Apolipoprotein A-1 in the media in which viable embryos developed, consistent with the data obtained in the MS profiling experiments and western blot analyses.
Further ELISA analysis was performed to determine the relative concentration of Apolipoprotein A-1 in individual media samples (VP, n ¼ 9; MP, n ¼ 6; NP, n ¼ 8; D, n ¼ 4; C, n ¼ 9]. Here, also the VP samples showed lowest levels (VP , MP , NP) confirming the trend observed with pooled samples, but the within-group variability was high in controls and resulted in no significant differences among groups (Fig. 4B , lower panel, P ¼ 0.06).
MRM analysis for Apolipoprotein A-1
The essential requirement for MRM technology is the ability to detect a specific precursor ion (Q1 m/z), to isolate that ion for collision-induced fragmentation and, finally, to detect a specific product ion (Q3 m/z), following fragmentation. Only ions with this exact transition are detected. The detection of the transitions triggers an enhanced product ion scan (EPI) of the precursor ion where fragmentation occurs in Q2 to generate an MS/MS spectrum that provides confirmation of the identity of the peptides. The Q1 mass 613.5417 corresponds to the doubly charged parent mass for the Apo-A1 1226 peptide (MH 2+ ) and the Q3 mass was the y7 (m/z 885.417) fragment which has a high intensity signal in the MS/MS spectrum data. The Q1/Q3 masses for the AQUA peptide are 618.77/ 895.417, respectively. In a first step, we developed an MRM internal calibration curve using a stable labeled isotope Apolipoprotein A-1 peptide. The AQUA peptide was diluted and used in LC-MRM-MS/MS analysis using 4-fold dilution steps from 1 pmol down to 60 attomols for injection. After data acquisition, the extracted ion chromatogram (XIC) for the Q1/Q3 was done. The area under the MRM LC peak is used to quantify the amount of the analyte present. In a typical quantification experiment, a standard concentration curve is generated using the synthetic AQUA peptide. When the unknown sample is then run under identical conditions, the concentration for the peptide in the unknown sample can be determined using the peak area and the standard concentration curve. Calibration curves were generated with the APO-A1 AQUA peptide DEPPQSPWDR* and were to quantify APO-A1 by using the area ratio of light peptide to heavy peptide from the XICs of the 613.5417/885.417 and 618.77/895.417 transitions, respectively. After data acquisition, the XICs peak areas were integrated and used to generate a calibration curve (Fig. 5A) . Each point for the curve was analyzed in triplicate by MRM. The calibration curved provides a linear curve with a high regression coefficient value, the dynamic range for detection and the LOQ and LOD. LC-MRM-MS was used to validate and quantify the relative amounts of the differentially expressed Apolipoprotein A-1 peptides that were identified in the profiling experiments.
The relative and absolute concentration of Apolipoprotein A-1 peptides in different categories of IVF media fluids were quantified in LC-MRM-MS experiments using a spiked synthetic peptide. Each sample was analyzed in three technical replicates experiments and five pooled samples were used for each medium category. The quantification was achieved by comparing the AUC for the internal standard peptide with that of the Apolipoprotein A-1 peptide in the different media pools using the XICs. Figure 5B shows the LC-MRM-MS/MS results for both the endogenous and the heavy synthetic corresponding Apolipoprotein A-1 peptides. The XIC for the Apolipoprotein A-1, the Apolipoprotein A-1 1236 AQUA 1226 endogenous and the Apolipoprotein A-1 1236 AQUA peptides, as well as the EPI scans with the MS/MS fragmentation spectra that identify the two peptides are shown in Supplementary data, Fig. S2 . The area integrations for the Apolipoprotein A-1 endogenous peptide and the Apolipoprotein A-1 AQUA peptides using the MultiQuant TM Software (ABISciex) for 
Discussion
Previous proteomics studies have been reported in the literature. Katz-Jaffe et al. (2006) examined protein biomarkers of development in mouse and human embryos using surface-enhanced laser desorption and ionization TOF. Results suggested the presence of different secretome profiles at various embryonic developmental stages. These results, however, have not been validated in further experiments and questions have been raised about this primary identification (Combelles and Racowsky, 2006) . Another study used protein microarrays to compare conditioned media from human embryos (implanted and non-implanted) before their transfer in a singleembryo transfer program. A few proteins were shown to be decreased and were, therefore, thought to be consumed by the human blastocyst. None of the proteins investigated was significantly up-regulated/secreted by the implanted blastocyst (Dominguez et al., 2009) . Further studies used proteomics in order to define the human embryonic secretome (Katz-Jaffe et al., 2009; McReynolds et al., 2011) . The latter authors reported that the protein lipocalin-1 could be detected in the secretome of human blastocysts (Day 5 embryos) and was associated with chromosome aneuploidy. Although significant differences were obtained for individual or pooled samples of euploid versus aneuploid embryos resulting in successful implantation, no predictive ability was documented regarding implantation potential by comparing pregnant and non-pregnant samples. In addition to the use of proteomics, a few publications have reported on the use of metabolomics as an alternative non-invasive method to diagnose implantation potential through the utilization of Raman and near infrared spectroscopies (Seli et al., 2007 (Seli et al., , 2011 Scott et al., 2008) . Recently, Rinaudo et al. (2012) reported that metabolomics assessment with nuclear magnetic resonance (NMR) (1H NMR) was not predictive of implantation. Therefore, more studies are needed to unequivocally demonstrate any clinical validity of these methods. Here, our first approach (MS profiling of WCX affinity-purified peptides) resulted in a classification algorithm generated for Day 3 transfers (standard day of transfer for many IVF clinics) that demonstrated a recognition capability of 41% for pregnancy (with MP samples) and 72% for failure to establish a pregnancy (NP) samples. The second approach using tandem affinity purification of peptides with WAX/WCX improved the GA with a recognition capability for embryo transfers resulting in pregnancy (MP group) of 71 -84% for the two surfaces tested and 71 -88% for prediction of poor embryo developmental competence (i.e. failed implantation).
While some of the peaks/peptides present in the GAs have not yet been identified, several peptides that were highly predictive in the algorithm were identified as fragments of Apolipoprotein A-1. These results were consistent across the experiments. Identification of the remaining peptides may be crucial for understanding the factors that determine embryo viability and successful implantation. In a third approach, we focused on the examination of this protein and analyzed its variations in the various categories of samples by immunoblotting and ELISA. Results of western blotting demonstrated a clear trend showing that the pregnant samples (live births) had decreased Apolipoprotein A-1; and ELISA results with pooled samples were confirmatory. The ELISA results with individual samples, however, showed variability within each category that made results not statistically significant, although the sample size was limited in those studies. In a final approach, we employed a quantitative MRM analysis of both individual and pooled media samples and we demonstrated a marked (almost 4-fold) decrease in the amount of the Apolipoprotein A-1 peptide with sequence DEPPQSPWDR in the media from embryos that successfully implanted and resulted in live births (VP group). MRM on a triple quadruple mass spectrometer was used because of its recognized ability to provide AQUA of targeted compounds in highly complex samples (Meng and Veenstra, 2011) . Consequently, this wellestablished verification assay was confirmatory of the biomarker candidates identified in the initial discovery stage.
The down-regulation of Apolipoprotein A-1 peptides and Apolipoprotein A-1 protein in the pregnancy groups (VP and MP) suggests that this protein may be internalized and/or metabolized by the more competent, viable embryos. Alternatively, it may be bound to ligands in the zona pellucida or embryo surface. Apolipoprotein A-1 is best known as the major protein component of circulating highdensity lipoprotein and the primary acceptor for cholesterol in extrahepatic tissues. Proteomic analyses of diverse tissue samples and body fluids other than serum have identified Apolipoprotein A-1 as a protein dysregulated in a variety of diseases (reviewed in Brosens et al., 2010) . The protective effects of Apolipoprotein A-1 are at least partly due to its ability to inhibit the synthesis of major inflammatory mediators, such as tumor necrosis factor and interleukin-1b, and to block cytokine-induced expression of selectins and other cellular adhesion molecules on endothelium, thereby diminishing neutrophil adherence and subsequent tissue injury identified as a putative anti-implantation factor secreted by the differentiating endometrium and inhibited by embryonic signals (Brosens et al., 2010) . It was speculated that Apolipoprotein A-1 may also serve to restrict embryo implantation to a confined period in the cycle and, conversely, that aberrant endometrial secretion of this lipoprotein contributes to implantation failure. Recent work showed that there is an abnormal endometrial protein profile in obese women at the time of implantation that could be involved in endometrial receptivity. An augmented local Apolipoprotein B presence indicated a possible efflux of low-density lipoprotein cholesterol toward the endometrium. The endometrium could be acting, therefore, as a cholesterol reservoir which may be needed upon embryo implantation (Tamarit et al., 2012) .
Within this context, it can be hypothesized that the competent viable embryos consume or metabolize this protein reflecting enhanced metabolic activity and/or creating a microenvironment of low Apoliprotein A-1 levels that could locally favor implantation. There were no temporal differences in peptide/protein profiling according to the number of days of culture, i.e. there were similar proteomic patterns on culture Days 2 and 3. It is well established that the human embryonic genome is switched on around the four to eight cell stage, which should occur on Day 3 of culture, and its metabolic and synthetic capacities shift at that point (Braude et al., 1998) . Recently, Mains et al. (2011) performed two-dimensional gel electrophoresis and MS of the culture media of human blastocysts. Apolipoprotein A-1 was increased in the culture media from goodquality blastocysts, but levels from Day 5 spent media could not be correlated with embryo implantation and pregnancy. Interestingly, Apolipoprotein A-1 mRNA transcripts were confirmed in blastocysts but not on Day 3 embryos. These results suggested a role for lipoproteins in early embryologic development. Our studies performed on embryos cultured until Day 3 provide evidence for embryonic use of the Apolipoprotein A-1 before its transcripts appear, suggesting that the cleaving embryo (pre-blastocyst stage) internalizes the lipoprotein for its own metabolic needs.
Using the current approach, it was not possible to identify the other differentially expressed peptides present in the algorithms or any other proteins not present in the culture medium (i.e. newly secreted embryonic products). This possibility cannot be ruled out as their intensities could be low or their masses might be very close to those of other peptides in the spectra making it difficult to isolate them in the precursor ion selector prior to the MS-MS analysis. The first limitation of a proteomic analysis is the requirement of large amounts of material (Seli et al., 2010) , and in IVF the media droplets may range from 20 to 50 ml as was our case. All the peptides/proteins that we were able to characterize so far in the conditioned media were also present in the control culture medium (which is a modified human serum substitute). This conclusion was reached after using both individual embryo culture media samples and pooled samples in order to achieve higher protein concentrations for the analytical studies. These findings also bring up the important issue of the total amount of protein theoretically secreted by two to eight-cell embryos and the sensitivity of the assays used (Ménézo et al., 2006) .
Previous studies have detected the expression of proteins in conditioned (spent) culture media from early embryos grown in vitro in a variety of species. Some of these molecules were identified in the human by immunological methods, including among others, paf (O'Neill, 2005) , HLA-G (Sher et al., 2005) , hCG (Ramu et al., 2011) , Apolipoprotein A1 (Mains et al., 2011) and superoxide dismutase-1 (Combelles et al., 2012) . However, there has been debate as to the reliability of some of these measurements. While it appears that the embryos may indeed release some of these signals, the sensitivity of the assays, the impact of IVF culture conditions (various media and protein supplements used clinically) and the true levels of the secreted molecules (orders of magnitude of the concentrations) have been questioned and require more extensive verification (Ménézo et al., 2006; Sargent et al., 2007) .
Considering the multifactorial nature of mammalian embryonic development, it would be reasonable to assume that more than one single factor/molecule would be required to predict embryonic implantation potential. This also raises the possibility that a panel of biomarkers discovered through a combined proteomic/metabolomic approach could aid in the development of an assay for clinical use. Our results demonstrated that peptide/protein profiles from the culture medium during early human in vitro development can discriminate embryos with highest and lowest implantation competence following uterine transfer, but further studies are needed to establish validated thresholds for clinical application. Simpler methods based on the detection of Apolipoprotein A-1 protein or derived peptides (by immunoassays or others) or perhaps of other newly identified products need to be characterized, and cut-offs and robust predictive power further validated and improved in follow-up studies. Further experiments should also be conducted to determine whether these biomarkers apply to different culture media/protein supplements (inter-media variability) and whether they are superior to current embryology methods, or whether they can be additive, extending the information provided by the morphological and other dynamic embryo assessments by a competent laboratory. Proteomics studies have identified the presence of complex sets of small protein fragments in plasma, the fragmentome or peptidome, a potentially rich source of information about physiologic and disease processes (Hortin et al., 2006) . However, for successful clinical application, all these methods have to demonstrate simplicity, high sensitivity and throughput, and must be cost-efficient, so that clinical embryology laboratories throughout the world can implement them.
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